chufangao/CTO huggingface dataset:
Clinical trial NCT03584009: A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Official title: A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Acronym: Veronica
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision, no safety concerns.
Enrollment: 103.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-06
Primary completion date: 2020-08-05
Completion date: 2021-05-06
Baseline population: Intent-To-Treat (ITT) population included all randomized participants whether or not they were assigned to the arm where the study treatment was administered.
Limitations and caveats: The study was terminated due to Sponsor's decision and there were no safety concerns. Primary and secondary efficacy endpoints have been updated to report 95% confidence interval (CI) for Clinical Benefit estimate and 95% CI for the Cox proportional hazards model for PFS, following reporting conventions.
Clinical trial NCT04543409: A Study of Benralizumab in Patients With Eosinophilic Esophagitis
Official title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis
Acronym: MESSINA
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints. Given the lack of clear benefit in this patient population, study has been terminated.
Enrollment: 211.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-22
Primary completion date: 2022-09-19
Completion date: 2023-02-06
Baseline population: All participants who were randomized and received any IP were included in the full analysis set.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT02562625: Trial of Pembrolizumab and Radiotherapy in Melanoma
Official title: Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
Acronym: PERM
Sponsor: Royal Marsden NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow Recruitment
Enrollment: 234.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-02-29
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Clinical trial NCT04378426: Nitrous Oxide for PTSD
Official title: Nitrous Oxide for Posttraumatic Stress Disorder (PTSD): A Phase IIa Trial
Acronym: N2OP
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Use of VA hospital research space is indefinitely delayed due to prioritization of clinical cases delayed by COVID
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-07
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Baseline population: Study discontinued due to unsufficient space due to backlog of clinical patients due to COVID
Limitations and caveats: The study was terminated in partnership with program officer given that the nitrous oxide administration space in the hospital (which had been used pre-pandemic) is longer available - it is being used exclusively for clinical care to keep up with the clinical backlog of cases due to the pandemic. This delay will continue for the foreseeable future. COVID-19 has had far-reaching impact on the feasibility of the study, which will not meet its recruitment goal in the foreseeable future.
Plan to share individual participant data: NO
IPD sharing description: No data will be shared without approval of sponsor and IRB.
Clinical trial NCT02687269: Ranolazine a Potential New Therapeutic Application
Official title: Ranolazine Myocardial Protection in Complete Coronary Artery Bypass Grafting: A Randomized-controlled Trial
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Inability to produce placebo tablets similar to the drug tested
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-10
Primary completion date: 2020-09-30
Completion date: 2020-10-31
Plan to share individual participant data: YES
Clinical trial NCT05490563: STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
Official title: A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar Ataxia
Acronym: STRIDES
Sponsor: Seelos Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: This was a business decision due to financial considerations, not based on data related to safety or therapeutic effects.
Enrollment: 23.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-06-03
Primary completion date: 2023-11-24
Completion date: 2023-11-24
Plan to share individual participant data: NO
Clinical trial NCT04697056: A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
Sponsor: AnaptysBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Administrative Reason
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-25
Primary completion date: 2021-11-19
Completion date: 2021-11-19
Baseline population: Intent-to-Treat (ITT) analysis set included all randomized participants.
Limitations and caveats: As a result of insufficient recruitment of participants, this study was terminated.
Clinical trial NCT03232307: Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
Official title: A Phase II Study of Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed MCL
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor does not wish to proceed
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-01
Primary completion date: 2021-07-01
Completion date: 2021-07-01
Clinical trial NCT04125719: PVSRIPO in Combination With Nivolumab in Melanoma
Official title: A Phase IB Trial of PVSRIPO in Combination With Nivolumab in Patients With Recurrent PD-1 Refractory Melanoma
Acronym: PPD1
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: resubmission planned
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2024-10-01
Completion date: 2024-10-01
Plan to share individual participant data: NO
Clinical trial NCT04088032: Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Official title: A Pilot Neoadjuvant Clinical Trial of Combination Therapy With Abemaciclib, Durvalumab (MEDI4736), and an Aromatase Inhibitor in Locally Advanced Hormone Receptor Positive Breast Cancer
Sponsor: Stony Brook University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Per sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-01
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT03570697: Imaging of Coronary Plaques in Participants Treated With Evolocumab
Official title: High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 164.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-19
Primary completion date: 2020-12-18
Completion date: 2021-01-21
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT00634231: A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Official title: A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Sponsor: Candel Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2010-10-31
Primary completion date: 2015-12-31
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT04460430: Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Official title: Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Acronym: NEREA
Sponsor: SOLTI Breast Cancer Research Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: premature termination due to lack of funding
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-23
Primary completion date: 2021-11-29
Completion date: 2021-11-29
Plan to share individual participant data: NO
Clinical trial NCT03423355: Dapagliflozin Effect on Erythropoiesis and Physical Fitness
Official title: Dapagliflozin Effect on Erythropoiesis and Physical Fitness in Patients With Type 2 Diabetes - a Randomized, Partly Double-blinded, Controlled, Three Armed, Parallel Group, Exploratory Study
Sponsor: University Hospital Tuebingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: change in sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-30
Primary completion date: 2023-03-31
Completion date: 2023-12-31
Clinical trial NCT02599402: Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Official title: Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401
Acronym: CheckMate 401
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 533.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-20
Primary completion date: 2020-02-10
Completion date: 2020-02-10
Clinical trial NCT02415257: Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function
Official title: Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With no Measurable Remaining Vestibular Function
Sponsor: Lund University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-04-30
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Clinical trial NCT04128371: Mepolizumab in Episodic Angioedema With Eosinophilia
Official title: Pilot Study of Mepolizumab in Episodic Angioedema With Eosinophilia
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was closed after the first five participants completed their participation due to lack of efficacy.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-14
Primary completion date: 2022-10-31
Completion date: 2022-10-31
Limitations and caveats: Study was closed due to futility
Clinical trial NCT05191628: Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole
Official title: Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole
Sponsor: TBF Genie Tissulaire (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual rate
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-10
Primary completion date: 2022-10-10
Completion date: 2022-10-10
Plan to share individual participant data: NO
Clinical trial NCT04357366: suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)
Official title: suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial
Acronym: SAVE
Sponsor: Hellenic Institute for the Study of Sepsis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 1000.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-15
Primary completion date: 2022-01-29
Completion date: 2022-04-15
Plan to share individual participant data: NO
Clinical trial NCT04539873: Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
Official title: Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
Acronym: (COLCOVID19)
Sponsor: Fundación Universitaria de Ciencias de la Salud (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: non-inclusion of patients in the study effectively
Enrollment: 128.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2021-10-30
Completion date: 2021-10-30
Plan to share individual participant data: NO
Clinical trial NCT03495713: Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
Official title: RadVax for Relapsed/Refractory Hodgkin's Lymphoma: A Phase II Trial of Nivolumab + Low Dose Radiotherapy for Incomplete Responders
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Covid-19
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-02
Primary completion date: 2022-04-20
Completion date: 2022-04-20
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04287478: Bacteriophage Therapy in Patients With Urinary Tract Infections
Official title: A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of Targeted Personalized Bacteriophage Treatments in Patients With Bacterial Infection of the Urinary Tract
Sponsor: Adaptive Phage Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to a change in development strategy.
Enrollment: 1.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-12-09
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Clinical trial NCT05372809: Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs
Official title: Closure Obtained With Vascularized Epithelial Regeneration for DFUs With SkinTE®
Acronym: COVER DFUs
Sponsor: PolarityTE (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study terminated due to slow enrollment and change in strategy.
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-28
Primary completion date: 2024-02-21
Completion date: 2024-02-21
Clinical trial NCT03551522: A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
Official title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: unexpected histological findings
Enrollment: 181.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-04-30
Primary completion date: 2019-05-08
Completion date: 2020-08-10
Plan to share individual participant data: NO
Clinical trial NCT04354428: Treatment for COVID-19 in High-Risk Adult Outpatients
Official title: Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Low number of events contributing to primary outcome
Enrollment: 289.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-04-16
Primary completion date: 2020-11-03
Completion date: 2020-11-30
Limitations and caveats: Early termination of HCQ and HCQ/AZ arms as well as lopinavir-ritonavir arms leading to small numbers of participants analyzed.
Plan to share individual participant data: YES
IPD sharing description: De-identified data from the study will be made available in accordance with the funder's open access policy.
IPD time frame: Within 3 months of publication of primary results.
IPD access criteria: De-identified data from the study will be made available in accordance with the funder's open access policy.
Clinical trial NCT03637764: Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Official title: A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was stopped after interim analysis for 4 cohorts (HCC, SCCHN, EOC, and GBM) indicated that the results did not fulfill the preplanned interim analysis criteria to move to Phase 2 stage 2 in all 4 cohorts.
Enrollment: 107.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-08-06
Primary completion date: 2022-05-11
Completion date: 2022-05-11
Baseline population: Analysis was performed on all-treated population that included all the participants who signed the study informed consent and received at least 1 dose of the study treatments, either isatuximab or atezolizumab.
Limitations and caveats: Study was stopped after performance of interim analysis for 4 cohorts (Cohort A \[HCC\], Cohort B \[SCCHN\], Cohort C \[EOC\] \& Cohort D-1 \[GBM\]) as the efficacy results observed in each cohort did not fulfill the pre-planned interim analysis criteria allowing the study to move to Phase 2 Stage 2 in these 4 cohorts.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT06091579: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
Official title: A Phase 1, Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Healthy Volunteers
Sponsor: Insmed Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-09-17
Primary completion date: 2021-01-12
Completion date: 2021-01-12
Plan to share individual participant data: NO
Clinical trial NCT02913612: Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
Official title: Efficacy, Safety, and Pharmacokinetics of Timolol in Infants With Infantile Hemangioma (IH)
Acronym: TIM01
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 105.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-05-05
Primary completion date: 2020-10-20
Completion date: 2020-10-20
Plan to share individual participant data: NO
Clinical trial NCT04418219: Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Official title: A Phase I/II Study of the SV-BR-1-GM Regimen in HLA Matched Metastatic Breast Cancer Patients in Combination With Pembrolizumab
Sponsor: Thomas Jefferson University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Funding Discontinued
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-21
Primary completion date: 2023-01-01
Completion date: 2024-01-01